Brokers' take: DBS retains 'buy' on IHH with S$2.32 target despite US lawsuit


IT IS untimely to find out the estimated potential legal responsibility that the authorized spat between US fund Emqore Envesecure Private Capital Trust and IHH Healthcare can have on the latter, because it entails numerous defendants and non-party defendants, mentioned DBS Group Research.

Comments are closed.